Effect_NN of_IN Lamivudine_NP on_IN Transmission_NP of_IN Human_NP T-Cell_NN Lymphotropic_JJ Virus_NP Type_NP 1_CD to_TO Adult_NP Peripheral_NP Blood_NP Mononuclear_NP Cells_NP In_IN Vitro_NP The_DT effects_NNS of_IN lamivudine_NP (_( 3TC_JJ )_) on_IN in_IN vitro_NN infection_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) from_IN healthy_JJ donors_NNS with_IN human_JJ T-cell_NN lymphotropic_JJ virus_NN type_NN 1_CD (_( HTLV-1_NP )_) were_VBD investigated_VBN ._SENT Direct_JJ measures_NNS of_IN viral_JJ replication_NN (_( viral_JJ DNA_NN ,_, RNA_NP ,_, and_CC protein_NN )_) all_RB gave_VBD similar_JJ ,_, very_RB high_RB 50_CD %_NN inhibitory_JJ concentrations_NNS in_IN comparison_NN with_IN those_DT previously_RB reported_VBN for_IN zidovudine_NP ._SENT Nevertheless_RB ,_, 3TC_NP inhibited_VBD HTLV-1-driven_NP long-term_JJ growth_NN of_IN infected_JJ PBMC_NN in_IN vitro_NN at_IN concentrations_NNS (_( 6.25_CD muM_NN )_) which_WDT had_VBD poor_JJ or_CC no_DT direct_JJ antiviral_JJ effects_NNS ,_, suggesting_VBG that_IN another_DT mechanism_NN may_MD be_VB playing_VBG a_DT role_NN ._SENT Lamivudine_NP (_( 3TC_NP )_) is_VBZ a_DT cytosine_NN nucleoside_NN reverse_JJ transcriptase_NN inhibitor_NN (_( NRTI_NP )_) that_WDT is_VBZ used_VBN ,_, in_IN combination_NN with_IN other_JJ nucleoside_NN or_CC nonnucleoside_JJ reverse_JJ transcriptase_NN inhibitors_NNS (_( NNRTIs_NP )_) or_CC protease_NN inhibitors_NNS (_( PIs_NP )_) ,_, in_IN the_DT treatment_NN of_IN infections_NNS caused_VBN by_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) ._SENT As_IN monotherapy_NN ,_, 3TC_NP is_VBZ used_VBN in_IN hepatitis_NP B_NP virus_NN (_( HBV_NP )_) infection_NN ._SENT Human_JJ T-cell_NN lymphotropic_JJ virus_NN type_NN 1_CD (_( HTLV-1_NP )_) is_VBZ the_DT etiological_JJ agent_NN of_IN adult_JJ T-cell_NN leukemia/lymphoma_NN (_( ATL_NP )_) and_CC of_IN demyelinating_VBG diseases_NNS characterized_VBN by_IN a_DT remarkable_JJ inflammatory_JJ response_NN ,_, known_VBN as_IN HTLV-1-associated_JJ human_JJ myelopathy/tropic_JJ spastic_JJ paraparesis_NN (_( HAM/TSP_NP )_) ._SENT ATL_NP has_VBZ a_DT poor_JJ prognosis_NN and_CC shows_VBZ high_JJ resistance_NN to_TO conventional_JJ chemotherapy_NN ._SENT Recent_JJ studies_NNS in_IN vivo_JJ have_VBP shown_VBN the_DT potential_JJ therapeutic_JJ utility_NN of_IN 3TC_JJ in_IN the_DT treatment_NN of_IN pathologies_NNS associated_VBN with_IN HTLV-1_JJ infection_NN ._SENT In_IN particular_JJ ,_, 3TC_JJ was_VBD found_VBN to_TO be_VB a_DT relatively_RB safe_JJ drug_NN that_WDT caused_VBD a_DT rapid_JJ fall_NN in_IN proviral_JJ load_NN in_IN HAM/TSP_NP patients_NNS ,_, although_IN phases_NNS of_IN decrease_NN in_IN viral_JJ load_NN alternated_VBN with_IN phases_NNS of_IN active_JJ replication_NN of_IN the_DT virus_NN ._SENT In_IN this_DT study_NN ,_, we_PP have_VBP assayed_VBN the_DT capacity_NN of_IN 3TC_JJ to_TO inhibit_VB infection_NN and_CC long-term_JJ growth_NN caused_VBN by_IN HTLV-1_NP in_IN vitro_NP ._SENT HTLV-1_JJ transmission_NN was_VBD performed_VBN by_IN coculturing_VBG peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) isolated_VBD from_IN normal_JJ adult_NN donors_NNS ,_, seronegative_JJ for_IN HIV_NP ,_, HBV_NP ,_, and_CC HCV_NP ,_, with_IN lethally_RB irradiated_JJ (_( 120_CD Cy_NP ;_: cesium_NN gamma_NN cell_NN irradiator_NN 1000_CD ;_: Canada_NP Atomic_NP Energy_NP Ltd._NP ,_, Chalk_NP River_NP ,_, Canada_NP )_) MT-2_NP cells_NNS at_IN a_DT ratio_NN of_IN 5:1_CD ._SENT MT-2_NP is_VBZ a_DT cell_NN line_NN chronically_RB infected_VBN by_IN HTLV-1_NP ._SENT To_TO assay_VB its_PP$ antiviral_JJ activity_NN ,_, 3TC_JJ (_( Wellcome_NP Research_NP Laboratories_NPS ,_, Beckenham_NP ,_, United_NP Kingdom_NP )_) was_VBD added_VBN at_IN final_JJ concentrations_NNS ranging_VBG from_IN 6.25_CD to_TO 100_CD muM_NN at_IN the_DT onset_NN of_IN the_DT culture_NN and_CC then_RB at_IN half_PDT the_DT initial_JJ concentrations_NNS 3_CD ,_, 7_CD ,_, and_CC 10_CD days_NNS postinfection_NN (_( p.i._JJ )_) to_TO ensure_VB a_DT constant_JJ level_NN of_IN the_DT drug_NN in_IN the_DT culture_NN medium_NN in_IN the_DT early_JJ phase_NN of_IN infection_NN ._SENT In_IN preliminary_JJ experiments_NNS ,_, lower_JJR concentrations_NNS of_IN 3TC_JJ did_VBD not_RB exert_VB any_DT antiviral_JJ effect_NN against_IN HTLV-1_NP in_IN vitro_NP ._SENT Concentrations_NNS of_IN 3TC_NN used_VBN were_VBD close_JJ to_TO the_DT peak_JJ levels_NNS in_IN serum_NN (_( 0.2_CD to_TO 20_CD muM_NN )_) which_WDT are_VBP detected_VBN in_IN patients_NNS treated_VBN with_IN pharmacological_JJ doses_NNS of_IN the_DT drug_NN ._SENT The_DT antiviral_JJ effects_NNS of_IN 3TC_JJ at_IN different_JJ concentrations_NNS were_VBD evaluated_VBN 4_CD weeks_NNS p.i._JJ by_IN assaying_VBG the_DT presence_NN of_IN proviral_JJ DNA_NN ,_, viral_JJ RNA_NP ,_, and_CC viral_JJ protein_NN expression_NN in_IN untreated_JJ and_CC treated_VBN cell_NN cultures_NNS ._SENT To_TO detect_VB proviral_JJ DNA_NN ,_, 1_CD mug_NN of_IN DNA_NP was_VBD used_VBN as_IN a_DT template_NN and_CC was_VBD amplified_VBN in_IN a_DT standard_JJ PCR_NP mix_NN by_IN using_VBG a_DT primer_JJR pair_NN specific_JJ for_IN the_DT pol_NN region_NN (_( SK54_NP and_CC SK56_NP )_) as_IN previously_RB described_VBN ._SENT To_TO detect_VB viral_JJ RNA_NP ,_, total_JJ RNA_NP from_IN infected_JJ cells_NNS was_VBD reverse_RB transcribed_VBN into_IN cDNA_NN and_CC amplified_VBN with_IN primers_NNS specific_JJ for_IN the_DT HTLV-1_NP Tax/Rex_NP splicing_VBG region_NN ._SENT Amplified_VBN DNA_NN was_VBD analyzed_VBN by_IN liquid_JJ hybridization_NN and_CC probed_VBN with_IN specific_JJ 32P-end-labeled_JJ oligonucleotides_NNS ._SENT Three_CD experiments_NNS using_VBG PBMC_NP from_IN different_JJ donors_NNS were_VBD performed_VBN with_IN similar_JJ results_NNS ._SENT Results_NNS of_IN one_CD representative_NN experiment_NN are_VBP reported_VBN in_IN Fig._NN ._SENT The_DT uninfected_JJ culture_NN used_VBN for_IN this_DT experiment_NN was_VBD designated_VBN PB-1_JJ ,_, while_IN the_DT infected_JJ culture_NN was_VBD designated_VBN PB-1/MT_NP ._SENT Addition_NN of_IN 100_CD muM_NN 3TC_JJ caused_VBN complete_JJ inhibition_NN of_IN proviral_JJ DNA_NN ,_, as_RB detected_VBN by_IN pol_NN primers_NNS and_CC viral_JJ RNA_NP ,_, compared_VBN to_TO the_DT untreated_JJ control_NN ._SENT Conversely_RB ,_, 25_CD and_CC 6.25_CD muM_NN 3TC_NN partly_RB inhibited_VBD the_DT presence_NN of_IN proviral_JJ DNA_NN ,_, and_CC 6.25_CD muM_NN 3TC_NN did_VBD not_RB inhibit_VB viral_JJ RNA_NP expression_NN ._SENT The_DT housekeeping_NN gene_NN glucose-6-phosphate_NN dehydrogenase_NN (_( G6PDH_NP )_) was_VBD present_JJ at_IN equal_JJ levels_NNS in_IN all_PDT the_DT samples_NNS for_IN both_DT DNA_NP and_CC RNA_NP ._SENT Expression_NN of_IN the_DT virus_NN protein_NN Tax_NN ,_, assayed_VBN by_IN Western_JJ blot_NN analysis_NN as_IN previously_RB described_VBN ,_, was_VBD completely_RB inhibited_VBN at_IN 100_CD and_CC 25_CD muM_NN 3TC_JJ ,_, while_IN 6.25_CD muM_NN 3TC_NN was_VBD not_RB inhibitory_JJ ._SENT Staining_VBG with_IN Ponceau_NP dye_NN indicated_VBD that_IN equal_JJ amounts_NNS of_IN proteins_NNS were_VBD analyzed_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM (_( A_NP )_) Presence_NP of_IN HTLV-1_NP proviral_JJ DNA_NN in_IN PB-1/MT_NP cell_NN cultures_VBZ 4_CD weeks_NNS p._NN (_( A_NP )_) Presence_NP of_IN HTLV-1_NP proviral_JJ DNA_NN in_IN PB-1/MT_NP cell_NN cultures_VBZ 4_CD weeks_NNS p.i._JJ (_( B_NP )_) Densitometric_NP analysis_NN of_IN genomic_JJ DNA_NN from_IN PB-1/MT_NP cultures_NNS ._SENT Absorbance_NN values_NNS (_( optical_JJ density_NN )_) refer_VBP to_TO amplification_NN of_IN genomic_JJ DNA_NN with_IN primers_NNS specific_JJ for_IN G6PDH_NP ._SENT (_( C_NP )_) Presence_NP of_IN HTLV-1_NP viral_JJ mRNA_NN in_IN PB-1/MT_NP cultures_NNS 4_CD weeks_NNS p.i._JJ (_( D_NP )_) Densitometric_NP analysis_NN of_IN total_JJ RNA_NP from_IN PB-1/MT_NP cultures_NNS 4_CD weeks_NNS p.i._JJ Absorbance_NP values_NNS (_( optical_JJ density_NN )_) refer_VBP to_TO amplification_NN with_IN primers_NNS specific_JJ for_IN G6PDH_NP ._SENT (_( E_NP )_) Expression_NN of_IN the_DT HTLV-1_NP protein_NN Tax_NN in_IN PB-1/MT_NP cultures_NNS 4_CD weeks_NNS p.i._JJ Western_NP blot_NN analysis_NN of_IN cell_NN lysates_NNS was_VBD performed_VBN ._SENT Blots_NNS were_VBD incubated_VBN overnight_RB at_IN 4C_JJ with_IN a_DT 1:1,000_CD dilution_NN of_IN an_DT anti-Tax_NN monoclonal_NN antibody_NN (_( a_DT generous_JJ gift_NN from_IN Elliot_NP Cowan_NP of_IN the_DT U.S._NP Food_NP and_CC Drug_NP Administration_NP Division_NP of_IN Transfusion-Transmitted_NP Diseases_NPS ,_, Bethesda_NP ,_, Md._NP )_) ._SENT (_( F_NP )_) Absorbance_NP values_VBZ (_( optical_JJ density_NN )_) obtained_VBN by_IN densitometric_JJ analysis_NN of_IN Tax_NP in_IN PB-1/MT_NP cultures_NNS ._SENT Lanes_NNS for_IN all_DT panels_NNS :_: 1_LS ,_, uninfected_JJ control_NN ;_: 2_LS ,_, untreated_JJ PB/MT-1_JJ cultures_NNS ;_: 3_CD through_IN 5_CD ,_, PB/MT-1_JJ cultures_NNS treated_VBN with_IN 100_CD ,_, 25_CD ,_, and_CC 6.25_CD muM_NN 3TC_JJ ,_, respectively_RB ._SENT Exposure_NN to_TO HTLV-1_NP in_IN vitro_NP usually_RB induces_VBZ proliferation_NN of_IN PBMC_NP ,_, leading_VBG in_IN most_JJS cases_NNS to_TO immortalization_NN of_IN infected_JJ cells_NNS ._SENT Since_IN these_DT are_VBP key_JJ hallmarks_NNS of_IN HTLV-1_JJ pathogenesis_NN ,_, the_DT effects_NNS of_IN 3TC_JJ on_IN cell_NN proliferation_NN were_VBD examined_VBN both_CC by_IN a_DT short-term_JJ assay_NN and_CC by_IN a_DT long-term_JJ growth_NN assessment_NN ._SENT To_TO assay_VB proliferation_NN at_IN early_JJ times_NNS p.i._NN ,_, PBMC_NP were_VBD cultivated_VBN ,_, alone_RB or_CC with_IN irradiated_JJ MT-2_JJ cells_NNS ,_, for_IN 7_CD days_NNS in_IN the_DT presence_NN of_IN interleukin_NN 2_CD (_( IL-2_NP )_) without_IN any_DT other_JJ stimulation_NN ._SENT 3TC_NP was_VBD added_VBN at_IN the_DT onset_NN of_IN the_DT cultures_NNS at_IN concentrations_NNS ranging_VBG from_IN 2_CD to_TO 800_CD muM_NN ._SENT Proliferation_NN was_VBD measured_VBN by_RB [_SYM 3H]thymidine_JJ (_( Amersham_NP Pharmacia_NP Biotech_NP ,_, Little_NP Chalfont_NP ,_, Buckinghamshire_NP ,_, United_NP Kingdom_NP )_) uptake_NN during_IN the_DT last_JJ 18_CD h_NN in_IN culture_NN ._SENT Figure_NN shows_VBZ the_DT results_NNS of_IN one_CD representative_NN experiment_NN in_IN quadruplicate_NN ,_, out_RB of_IN four_CD performed_VBN with_IN cells_NNS from_IN different_JJ donors_NNS ._SENT In_IN uninfected_JJ cultures_NNS ,_, 800_CD muM_NN 3TC_NN significantly_RB inhibited_VBD cell_NN proliferation_NN (_( P_NN =_SYM 0.001_CD by_IN the_DT two-sided_JJ Dunnett_NP 's_POS pairwise_JJ multiple-comparison_NN t_NN test_NN )_) ._SENT There_EX were_VBD no_DT significantly_RB different_JJ effects_NNS at_IN the_DT other_JJ 3TC_JJ concentrations_NNS ._SENT Cultures_NNS were_VBD promptly_RB induced_VBN to_TO proliferate_VB following_VBG HTLV-1_JJ infection_NN (_( twofold_JJ increase_NN )_) ,_, as_RB shown_VBN by_IN comparing_VBG thymidine_NN uptake_NN in_IN untreated_JJ PB-1/MT_NP versus_CC untreated_JJ PB-1_JJ cultures_NNS ._SENT In_IN infected_JJ cultures_NNS ,_, high_JJ concentrations_NNS of_IN 3TC_JJ (_( 100_CD to_TO 800_CD muM_NN )_) caused_VBD marked_JJ inhibition_NN of_IN thymidine_NN uptake_NN (_( P_NN <_SYM 0.001_CD relative_NN to_TO untreated_JJ infected_JJ cultures_NNS by_IN the_DT two-sided_JJ Dunnett_NP 's_POS pairwise_JJ multiple-comparison_NN t_NN test_NN )_) ._SENT In_IN order_NN to_TO examine_VB the_DT consequences_NNS of_IN 3TC_JJ treatment_NN on_IN the_DT long-term_JJ growth_NN of_IN HTLV-1-infected_NP PBMC_NP ,_, cells_NNS that_WDT were_VBD either_RB left_VBN untreated_JJ or_CC treated_VBN with_IN 3TC_NP were_VBD maintained_VBN in_IN culture_NN for_IN 13_CD weeks_NNS ._SENT Cell_NN growth_NN was_VBD monitored_VBN weekly_JJ by_IN evaluating_VBG the_DT living-cell_NN count_NN by_IN use_NN of_IN the_DT trypan_JJ blue_JJ dye_NN exclusion_NN test_NN ,_, calculated_VBN as_IN the_DT mean_NN of_IN two_CD independent_JJ evaluations_NNS ._SENT After_IN counting_NN ,_, cell_NN concentrations_NNS were_VBD adjusted_VBN to_TO 1_CD x_SYM 106/ml_JJ ._SENT Results_NNS were_VBD expressed_VBN as_IN total_JJ cell_NN number_NN (_( TCN_NP )_) ,_, calculated_VBN from_IN weekly_JJ cell_NN counts_NNS as_RB follows_VBZ ._SENT For_IN the_DT first_JJ week_NN ,_, TCN_NP was_VBD the_DT number_NN of_IN cells_NNS (_( expressed_VBN as_IN millions_NNS of_IN viable_JJ cells_NNS per_IN milliliter_NN )_) detected_VBN before_IN the_DT first_JJ adjustment_NN ._SENT On_IN successive_JJ weeks_NNS ,_, TCN_NP was_VBD calculated_VBN as_IN the_DT TCN_NP at_IN the_DT previous_JJ weekly_JJ passage_NN multiplied_VBN by_IN the_DT number_NN of_IN cells_NNS (_( expressed_VBN as_IN millions_NNS of_IN viable_JJ cells_NNS per_IN milliliter_NN )_) detected_VBN before_IN weekly_JJ adjustment_NN ._SENT Figure_NN shows_VBZ the_DT mean_JJ TCNs_NP +-_NN standard_NN deviations_NNS (_( SD_NP )_) from_IN three_CD different_JJ experiments_NNS using_VBG PBMC_NP from_IN three_CD donors_NNS ._SENT Uninfected_JJ cultures_NNS grew_VBD poorly_RB when_WRB maintained_VBN in_IN IL-2_NP without_IN additional_JJ stimuli_NNS throughout_IN the_DT time_NN of_IN observation_NN (_( Fig._NN ,_, C_NP ,_, and_CC E_NN )_) ._SENT Infected_JJ cultures_NNS treated_VBN with_IN 100_CD or_CC 25_CD muM_NN 3TC_NN ceased_VBD to_TO grow_VB after_IN 5_CD and_CC 7_CD weeks_NNS ,_, respectively_RB ._SENT Infected_JJ cultures_NNS treated_VBN with_IN 6.25_CD muM_NN 3TC_NN survived_VBD to_TO 9_CD weeks_NNS p.i._JJ ._SENT Conversely_RB ,_, all_DT infected_JJ untreated_JJ cultures_NNS were_VBD still_RB growing_VBG at_IN week_NN 13_CD ,_, when_WRB the_DT experiments_NNS were_VBD interrupted_VBN ._SENT FIG._NN 2_CD ._SENT |_SYM Effects_NN of_IN different_JJ concentrations_NNS of_IN 3TC_JJ on_IN the_DT proliferative_JJ responses_NNS of_IN PB-1_JJ cell_NN cultures_NNS left_VBD unexposed_JJ (_( A_NP )_) or_CC exposed_VBN to_TO HTLV-1_NP (_( PB-1/MT_NP )_) (_( B_NP )_) ._SENT Effects_NNS of_IN different_JJ concentrations_NNS of_IN 3TC_JJ on_IN the_DT proliferative_JJ responses_NNS of_IN PB-1_JJ cell_NN cultures_NNS left_VBD unexposed_JJ (_( A_NP )_) or_CC exposed_VBN to_TO HTLV-1_NP (_( PB-1/MT_NP )_) (_( B_NP )_) ._SENT Results_NNS are_VBP expressed_VBN as_IN mean_JJ counts_NNS per_IN minute_NN of_IN radioactivity_NN +-_NN SD_NN from_IN quadruplicate_JJ samples_NNS ._SENT Bars_NNS :_: 1_LS ,_, untreated_JJ PB-1_NP or_CC PB-1/MT_NP ;_: 2_CD through_IN 9_CD ,_, cultures_NNS treated_VBN with_IN 3TC_JJ at_IN 2_CD muM_NN (_( bar_NN 2_CD )_) ,_, 6.25_CD muM_NN (_( bar_NN 3_CD )_) ,_, 25_CD muM_NN (_( bar_NN 4_CD )_) ,_, 100_CD muM_NN (_( bar_NN 5_CD )_) ,_, 200_CD muM_NN (_( bar_NN 6_CD )_) ,_, 400_CD muM_NN (_( bar_NN 7_CD )_) ,_, 600_CD muM_NN (_( bar_NN 8_CD )_) ,_, or_CC 800_CD muM_NN (_( bar_NN 9_CD )_) ._SENT Results_NNS were_VBD obtained_VBN from_IN a_DT single_JJ donor_NN ,_, designated_VBN PB-1_NP ,_, representative_NN of_IN four_CD donors_NNS tested_VBD ._SENT FIG._NN 3_CD ._SENT |_SYM Growth_NN curves_NNS of_IN uninfected_JJ PBMC_NP (_( A_NP ,_, C_NP ,_, and_CC E_NP )_) and_CC HTLV-1_NP infected_JJ PBMC_NP (_( B_NP ,_, D_NP ,_, and_CC F_NN )_) in_IN the_DT presence_NN of_IN different_JJ concentrations_NNS of_IN 3TC_JJ ._SENT Growth_NN curves_NNS of_IN uninfected_JJ PBMC_NP (_( A_NP ,_, C_NP ,_, and_CC E_NP )_) and_CC HTLV-1_NP infected_JJ PBMC_NP (_( B_NP ,_, D_NP ,_, and_CC F_NN )_) in_IN the_DT presence_NN of_IN different_JJ concentrations_NNS of_IN 3TC_JJ ._SENT Each_DT experimental_JJ point_NN represents_VBZ the_DT mean_JJ TCN_NP +-_NN SD_NN determined_VBN weekly_RB in_IN cultures_NNS from_IN three_CD different_JJ experiments_NNS using_VBG PBMC_NP from_IN three_CD donors_NNS ._SENT The_DT growth_NN curve_NN of_IN untreated_JJ cultures_NNS is_VBZ reported_VBN in_IN all_DT graphs_NNS ,_, for_IN visual_JJ comparison_NN ._SENT By_IN one-way_JJ analysis_NN of_IN variance_NN ,_, significant_JJ differences_NNS in_IN HTLV-1-infected_NP PBMC_NP among_IN groups_NNS were_VBD determined_VBN starting_VBG by_IN week_NN 3_CD ,_, while_IN no_DT differences_NNS in_IN uninfected_JJ PBMC_NN among_IN groups_NNS were_VBD found_VBN at_IN any_DT times_NNS tested_VBD ._SENT Different_JJ measures_NNS of_IN the_DT antiviral_JJ effects_NNS of_IN 3TC_JJ in_IN HTLV-1_NP infection_NN were_VBD compared_VBN by_IN calculating_VBG the_DT 50_CD %_NN inhibitory_JJ concentrations_NNS (_( IC50s_NP )_) for_IN proviral_JJ DNA_NN ,_, viral_JJ RNA_NP ,_, and_CC Tax_NP detection_NN ,_, as_RB previously_RB shown_VBN for_IN other_JJ NRTIs_NP ._SENT Means_NP +-_NN SD_NN of_IN three_CD IC50_NP evaluations_NNS ,_, calculated_VBN from_IN all_DT data_NNS obtained_VBN in_IN three_CD experiments_NNS performed_VBD using_VBG PBMC_NN from_IN different_JJ donors_NNS ,_, were_VBD as_RB follows_VBZ :_: 29_CD +-_NN 2_CD muM_NN for_IN proviral_JJ DNA_NN (_( pol_NN )_) ,_, 24_CD +-_NN 2_CD muM_NN for_IN viral_JJ RNA_NP (_( tax/rex_NP )_) ,_, and_CC 14_CD +-_NN 1_CD muM_NN for_IN Tax_NP protein_NN (_( the_DT Pearson_NP coefficient_NN [_SYM r2_NN ]_SYM for_IN the_DT y_NP value_NN was_VBD 0.9_CD )_) ._SENT IC50s_NNS were_VBD calculated_VBN according_VBG to_TO the_DT best-fit_NN curve_NN (_( y_NN value_NN versus_CC log_NN x_NN ,_, where_WRB y_NP is_VBZ the_DT value_NN of_IN the_DT function_NN examined_VBD and_CC x_NN is_VBZ the_DT drug_NN concentration_NN )_) ._SENT These_DT results_NNS show_VBP that_IN IC50s_NP calculated_VBN from_IN proviral_JJ DNA_NN and_CC viral_JJ RNA_NP assays_NNS were_VBD about_RB twice_RB as_RB high_JJ as_IN the_DT IC50_NP for_IN Tax_NP expression_NN ,_, suggesting_VBG a_DT possible_JJ effect_NN of_IN 3TC_JJ at_IN the_DT translational_JJ level_NN ._SENT 3TC_NP completely_RB inhibited_VBD proviral_JJ DNA_NN ,_, viral_JJ mRNA_NN ,_, and_CC protein_NN expression_NN only_RB at_IN a_DT high_JJ concentration_NN (_( 100_CD muM_NN )_) ._SENT This_DT concentration_NN is_VBZ out_RP of_IN the_DT range_NN which_WDT can_MD be_VB considered_VBN pharmacological_JJ on_IN the_DT basis_NN of_IN clinical_JJ experience_NN with_IN HIV_NP infection_NN ._SENT Moreover_RB ,_, the_DT antiviral_JJ potency_NN of_IN 3TC_JJ against_IN HTLV-1_JJ transmission_NN is_VBZ more_JJR than_IN 100_CD times_NNS lower_JJR than_IN that_DT of_IN zidovudine_NP (_( AZT_NP )_) ,_, as_RB determined_VBN by_IN comparing_VBG IC50s_NNS presented_VBN in_IN this_DT paper_NN with_IN those_DT previously_RB reported_VBN ._SENT This_DT is_VBZ different_JJ from_IN what_WP has_VBZ been_VBN observed_VBN for_IN HIV_NP infection_NN ,_, where_WRB inhibitory_JJ concentrations_NNS of_IN 3TC_NP and_CC AZT_NP are_VBP similar_JJ ._SENT The_DT discrepancy_NN between_IN the_DT behaviors_NNS of_IN HIV_NP and_CC HTLV-1_NP when_WRB subjected_VBN to_TO 3TC_JJ treatment_NN might_MD be_VB due_JJ to_TO a_DT different_JJ capacity_NN of_IN 3TC_JJ to_TO interact_VB with_IN the_DT reverse_JJ transcriptase_NN (_( RT_NP )_) of_IN HIV_NP and_CC HTLV-1_NP ,_, respectively_RB ._SENT This_DT hypothesis_NN is_VBZ strongly_RB supported_VBN by_IN biochemical_JJ results_NNS showing_VBG high-level_JJ resistance_NN to_TO 3TC_JJ in_IN HTLV-1_NP RT_NP by_IN use_NN of_IN an_DT enzymatic_JJ assay_NN ._SENT The_DT YMDD_JJ site_NN ,_, the_DT most_RBS frequent_JJ source_NN of_IN mutations_NNS conferring_VBG resistance_NN to_TO 3TC_JJ in_IN HIV_NP ,_, seems_VBZ well_RB conserved_VBN in_IN the_DT RT_NP of_IN HTLV-1_NP ._SENT Therefore_RB ,_, a_DT site_NN other_JJ than_IN YMDD_NP could_MD be_VB responsible_JJ for_IN a_DT possible_JJ low_JJ conformational_JJ affinity_NN of_IN 3TC_JJ to_TO HTLV-1_NP RT_NP ._SENT While_IN 6.25_CD muM_NN 3TC_NN showed_VBD no_DT signs_NNS of_IN antiviral_JJ or_CC short-term_JJ antiproliferative_JJ activity_NN ,_, this_DT dose_NN was_VBD nevertheless_RB able_JJ to_TO arrest_VB growth_NN in_IN the_DT long-term_JJ assay_NN of_IN infected_JJ cells_NNS ._SENT This_DT fact_NN suggests_VBZ that_IN 3TC_NP may_MD counteract_VB long-term_JJ growth_NN by_IN mechanisms_NNS other_JJ than_IN antiviral_JJ effect_NN ,_, possibly_RB affecting_VBG HTLV-1-infected-cell_NN activity_NN ._SENT Inhibition_NN of_IN long-term_JJ cell_NN growth_NN in_IN infected_JJ cells_NNS might_MD be_VB due_JJ to_TO relatively_RB high-level_JJ incorporation_NN and_CC ,_, possibly_RB ,_, phosphorylation_NN of_IN 3TC_JJ in_IN cells_NNS chronically_RB infected_VBN by_IN the_DT virus_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, protection_NN against_IN immortalization_NN by_IN 6.25_CD muM_NN 3TC_JJ could_MD be_VB related_VBN to_TO the_DT partial_JJ ,_, if_IN not_RB complete_JJ ,_, inhibitory_JJ action_NN on_IN Tax_NP transactivating_VBG protein_NN expression_NN caused_VBN by_IN the_DT drug_NN at_IN this_DT concentration_NN ._SENT Inhibition_NN of_IN long-term_JJ cell_NN growth_NN in_IN HTLV-1-infected_JJ cells_NNS in_IN vitro_NN could_MD explain_VB ,_, at_IN least_JJS in_IN part_NN ,_, the_DT effects_NNS exerted_VBN by_IN 3TC_JJ in_IN HTLV-1-infected_JJ patients_NNS in_IN vivo_RB ._SENT Another_DT noteworthy_JJ point_NN is_VBZ that_DT 3TC_JJ ,_, in_IN spite_NN of_IN its_PP$ ability_NN to_TO inhibit_VB long-term_JJ growth_NN of_IN HTLV-1-infected_JJ cultures_NNS ,_, was_VBD shown_VBN to_TO be_VB less_RBR potent_JJ than_IN AZT_NP in_IN inhibiting_VBG the_DT proliferation_NN of_IN either_DT uninfected_JJ or_CC freshly_RB HTLV-1-infected_JJ cultures_NNS ,_, based_VBN on_IN a_DT historical_JJ comparison_NN with_IN previous_JJ results_NNS ._SENT This_DT observation_NN indicates_VBZ a_DT low_JJ level_NN of_IN immunotoxicity_NN for_IN this_DT drug_NN ,_, which_WDT could_MD be_VB potentially_RB beneficial_JJ for_IN patients_NNS undergoing_VBG therapy_NN ._SENT Taken_VBN together_RB ,_, these_DT data_NNS demonstrate_VBP that_IN 3TC_NP has_VBZ little_JJ in_IN vitro_NP antiviral_JJ activity_NN against_IN HTLV-1_JJ infection_NN at_IN clinically_RB relevant_JJ concentrations_NNS and_CC therefore_RB is_VBZ unlikely_JJ to_TO have_VB direct_JJ antiviral_JJ efficacy_NN in_IN HTLV-1-infected_JJ patients_NNS ._SENT Rather_RB ,_, indirect_JJ effects_NNS could_MD explain_VB its_PP$ limited_JJ clinical_JJ benefit_NN in_IN HTLV-1_JJ infection_NN in_IN vivo_RB ._SENT 